Registration successful.
Account activated – Pending validation
Your account has been activated successfully, but we still need to validate you as a UK healthcare professional. We’ll send you an email with the result. Please note this could take up to 10 days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website.
249 result(s)
Ellipta inhaler
27-11-2015
Ellipta inhaler information for UK healthcare professionals including getting started, how to use the Ellipta inhaler and top tips for your patients.
Homepage
GSKpro is exclusively created for healthcare professionals to provide GSK product related information, services and support.
Sitemap
GlaxoSmithKline (GSK) UK healthcare professional website site map.
GSK support for healthcare professionals in response to COVID-19
Information for healthcare professionals on GSK’s response to COVID-19, where to find support and relevant resources.
DECTOVA▼
Zanamivir IV</br> Influenza
ZEJULA▼
Niraparib<br>Oncology
Requip & Adartrel (Ropinirole) artwork change | GSKpro
Information for changes to the colour of the ink on both the cartons and blister packs of Requip and a blister pack of Adartrel.
FAQ | Supply | GSKpro
Frequently asked questions around the supply and availability of GSK medicines and vaccines.
COPD expert perspectives
Watch GSK Global Medical Experts approach key issues in COPD treatment, offering solutions for UK healthcare professionals.
Medicines management and optimisation
Access bespoke financial and prescribing data for your health economy. Identify variability, track and optimise your implementation projects
GSK Highlights from ATS 2020 | GSKpro
GSK Highlights from The American Thoracic Society (ATS) Congress 2020
Ellipta critical error studies in COPD
Information about the benefits of GSK's Ellipta inhaler for UK healthcare professionals to support their COPD patients
GSK Highlights from ERS 2020 | GSKpro
GSK Highlights from European Respiratory Congress 2020
Respiratory
Overview of COPD and severe asthma.
Oncology Expert Insights
Expert opinion on ovarian cancer treatment to support UK healthcare professionals
Ordering and delivery
Find out how to set up an account and start ordering GSK vaccines.
Therapy areas
GSK UK therapy areas page allows healthcare professionals to find GSK product information by therapy area.
Request a contact
Contact us form for UK healthcare professionals to contact GSK
Report Adverse Event
Form for UK healthcare professionals to report an adverse event related to a GSK product
Zejula ▼ (niraparib)
Zejula ▼ (niraparib) product information for healthcare professionals detailing the top line efficacy, safety and dosing data
Resources
Zejula ▼ (niraparib) resources, including presentations from key experts discussing the management of ovarian cancer within the UK and debating the relevance and implications of ‘hot topics’ in patient care
Varilrix
Varilrix – Chickenpox/varicella vaccine product information to support UK healthcare professionals
Patient stories | Seretide (salmeterol/fluticasone propionate)
Patient stories with Seretide Evohaler (salmeterol/fluticasone propionate)
Seretide inhaler technique and safety
Videos and materials to help you ensure your patients are using their Seretide Accuhaler and Evohaler correctly.
Adartrel
Adartrel (ropinirole hydrochloride) - links to the summary of product characteristics, patient information leaflet and supply information to support UK healthcare professionals.
Cost | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) price information to support UK healthcare professionals
Dose & Device | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) dosing and device information to support UK healthcare professionals
Guidelines |Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)| GSKPro
Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals
Identifying patients | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals
Safety Information | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals
HRQoL | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals
Lung Function | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals
Efficacy
Trelegy Ellipta is a Triple Therapy indicated for maintenance treatment in adult patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an ICS and a LABA.
Home | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals
Dosing & Administration | Nucala (mepolizumab)
Nucala (mepolizumab) can be administered at home or in clinic. Read more about dosing and administration here.
Identifying Patients | Nucala (mepolizumab)
Understand how to identify which patients with severe asthma are suitable for treatment with Nucala (mepolizumab) as an add-on treatment.
Paediatric Patients | Nucala (mepolizumab)
See the data behind and safety profile of Nucala (mepolizumab) in paediatric patients with severe asthma.
Safety Information | Nucala (mepolizumab)
See the safety profile of Nucala (mepolizumab) in adults and adolescents.
Efficacy | Nucala (mepolizumab)
Read the clinical data about Nucala (mepolizumab).
Resources | Nucala (mepolizumab)
View other resources to support you and your patients using Nucala (mepolizmab) as an add on treatment for adults, adolescents and children over 6 years old with severe refractory eosinophilic asthma.
Nucala (meplizumab) | Severe eosinophilic asthma
Learn more about Nucala (mepolizumab) as an add-on treatment for patients with severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.
Video Testimonials: I've Seen Meningitis
Video testimonials from healthcare professionals about the impact of meningitis
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) I COPD I GSKPro
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals
Vaccines
GSK UK information about our vaccines and disease awareness campaigns
Expert Perspectives | Nucala (mepolizumab)
See what the experts have to say about Nucala (mepolizumab).
Products
GSK product information for UK healthcare professionals
Molecules | Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol)
Trelegy ▼ Ellipta (fluticasone furoate/umeclidinium/vilanterol) information to support UK healthcare professionals
Discontinued products | GSK Pro
Discontinued products
Contact | GSKpro UK
GSK UK contact page for healthcare professionals.
Supply
Information to be provided to Healthcare Professionals on GSK’s medicines and vaccines supply availability
No results. Why not try:
- Checking the spelling of the search term
- Trying a different search term
- Resetting or revising the filter settings (if you used filters to do this search)
Show more
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441.
